ArticleBrain communications2026
Structural, functional and neurochemical imaging mapping of non-motor symptoms in Parkinson's disease.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-motor symptoms, including rapid eye movement sleep behaviour disorder (RBD), depression and anxiety, are common and often co-occurring in patients with Parkinson's disease. This study aimed to investigate their potential shared neurobiological substrates by integrating structural, functional and neurochemical imaging data. We analysed data from 638 Parkinson's disease patients from the Parkinson's Progression Markers Initiative (PPMI), with available 3T T1-weighted MRI scans. RBD, depression and anxiety severity were assessed using validated clinical scales (RBD Screening Questionnaire Score, Geriatric Depression Scale and State-Trait Anxiety Inventory). Voxel-based morphometry (VBM) multivariate regression analyses were performed to identify grey matter (GM) volume loss associated with each clinical symptom. All analyses were rigorously controlled for a comprehensive set of potential confounders, including age, sex, education, disease duration, motor severity and cognitive dysfunction, thereby minimizing confounding effects related to other aspects of the disease. Coordinate-based network mapping was then applied using a large normative resting-state functional connectome (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.